News

AstraZeneca and Eli Lilly and Company have reached an agreement for the development and commercialization of the oral beta secretes cleaving enzyme (BACE) inhibitor, AZD3293, which might become a viable treatment for Alzheimer’s disease. The oral therapy is expected to prevent the formation of…

Avanir Pharmaceuticals Inc. reported today new, positive results for their leading drug, AVP-923, designed to treat agitation in Alzheimer’s disease patients. The results will be presented at the American Neurological Association’s (ANA) 2014 Annual Meeting in Baltimore, MD, October 12-14, 2014. Joao Siffert, MD, chief medical officer at Avanir,…

The human brain has the plasticity to compensate for the accumulation of the protein beta-amyloid that causes Alzheimer’s disease, which explains that some individuals develop it and others don’t, as concluded by research conducted at the University of California in Berkeley (UC Berkeley). The researchers analyzed adults with and without beta-amyloid deposits…

A Phase 2 randomized, double blind, placebo-controlled, parallel group study is currently enrolling at multiple test centers in the United States to evaluate the efficacy and safety of T-817MA as a potential treatment in patients with mild to moderate Alzheimer’s disease. This study is a joint phase II clinical…

A new Open Access study published in the prestigious BMJ journal finds indication that use of benzodiazepines, widely prescribed drugs for treatment of anxiety and insomnia, is associated with an increased risk of developing Alzheimer’s disease, particularly for long-term users. These drugs, medically referred to as benzodiazepine receptor agonists,…

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Boston-based software company OnDeckBiotech are launching a new open access platform with the purpose of creating an improved way to connect scientists with a virtual network of contract research organizations (CROs), drug development experts, and educational resources. The announcement was made on third day of…

For diseases that science has yet to find a cure, researchers are hard at work developing preventive medicine, better diagnostic tools, and risk calculation methods. A biotech company that specializes in advancing serum-based assays for neurodegenerative conditions has just announced an exclusive Fall 2014 release of a patented test that can predict the development…

The identification of a genetic variant may lead to improved diagnostics for predicting the onset of Alzheimer’s disease. Amyloid-beta (Aβ) is the main component of amyloid plaques, i.e., extracellular deposits in the brains of patients with Alzheimer’s disease. Now, a new study entitled “Apolipoprotein E Genotype and…

Featureflash / Shutterstock.com Actress Julianne Moore is starring a movie about the struggle against Alzheimer’s disease, a drama about a 50-year-old college professor who is diagnosed with Early-onset Familial Alzheimer’s. In addition, the movie is looking to raise awareness about the disease and show what it…

Back in 2005, researchers published findings on Alzheimer’s Disease that were quite bold, linking insulin deficiency with an increased risk for amyloid plaque build up. Amyloid plaque has been associated with this common form of dementia since the early 2000s, and is believed to cause the neurodegenerative…